EcoDrugPlus

Somatostatin Receptor 2

Ensembl ID : ENSOKIG00005019260
Gene Symbol: SSTR2
1 Cross references
186 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSOKIG00005050036
Gene Symbol: SSTR2
3 Cross references
189 Possible Orthologues:

Somatostatin Receptor 2

Ensembl ID : ENSOKIG00005035797
Gene Symbol: SSTR2
3 Cross references
189 Possible Orthologues:

Sphingosine 1-Phosphate Receptor 1

Ensembl ID : ENSOKIG00005026382
Gene Symbol: LOC109887980
3 Cross references
194 Possible Orthologues:

Sphingosine 1-Phosphate Receptor 1

Ensembl ID : ENSOKIG00005016263
Gene Symbol: LOC109902341
3 Cross references
194 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSOKIG00005034707
Gene Symbol: LOC109883204
2 Cross references
194 Possible Orthologues:

Sphingosine Kinase 2-Like

Ensembl ID : ENSOKIG00005002342
Gene Symbol: LOC109884473
2 Cross references
194 Possible Orthologues:

Spleen Associated Tyrosine Kinase

Ensembl ID : ENSOKIG00005050895
Gene Symbol: SYK
3 Cross references
200 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2a

Ensembl ID : ENSOKIG00005026675
Gene Symbol: SRD5A2A
1 Cross references
202 Possible Orthologues:

Steroid-5-Alpha-Reductase, Alpha Polypeptide 2b

Ensembl ID : ENSOKIG00005031212
Gene Symbol: SRD5A2B
1 Cross references
191 Possible Orthologues:

Sterol O-Acyltransferase 1-Like

Ensembl ID : ENSOKIG00005027245
Gene Symbol: LOC116352802
3 Cross references
210 Possible Orthologues:

Stress Response Protein Nst1-Like

Ensembl ID : ENSOKIG00005037287
Gene Symbol: LOC109898283
2 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).